Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
11 Cards in this Set
- Front
- Back
- 3rd side (hint)
|
Name the drug classes used for Parkinson's disease.
|
Dopamine agonists, MAO inhibitors, Antimuscarinics, COMT inhibitors
|
Remember B/A/L/S/A
|
|
|
Name the Dopamine agonists.
|
L-dopa/carbidopa, bromocriptine (an ergot alkaloid and partial dopamine agonist), pramipexole, ropinirole, amantadine (enhances dopamine release).
|
|
|
|
Name the MAO inhibitors.
|
Seleginline (selective MAO type B inhibitor)
|
|
|
|
Name the antimuscarinics
|
Benztropine (imporves tremor and rigidity but has little effect on bradykinesia)
|
|
|
|
Name the COMT inhibitors
|
Entacapone, tolcapone (adjunct to levodopa)
|
b/c levodopa broken down in peripery by comt-leaving more for brain
|
|
|
What is the mechanism L-dopa (levodopa)/carbidopa?
|
increaseslevel of dopamine in brain. L-dopa can cross bloodbrain barrier and is converted by dopa decarboxylase in the CNS to dopamine.
|
|
|
|
What is the clinical use for L-dopa?
|
Parkinsonism
|
|
|
|
The toxicity of L-dopa implications are?
|
Arrhythmias from peripheral conversion to dopamine. Cardidopa, a periperal decarboxylase inhibitor, is given with L-dopa in order to increase the bioavailability of L-dopa in the braiin and to limit peripheral side effects.
|
Dyskinesias also occurs.
|
|
|
What is the mechanism for Selegiline (deprenyl)?
|
Selectively inhibits MAO-B, thereby increasing the availablity of dopamine.
|
|
|
|
What is the clinical use of deprenyl?
|
Adjunctive agent to L-dopa in treatment of Parkinson's disease.
|
Also called Selegiline
|
|
|
What are the toxicity implications?
|
May enhance adverse effects of L-dopa.
|
|
